Vericel Corporation $VCEL Stock Holdings Raised by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS raised its stake in Vericel Corporation (NASDAQ:VCEL) by 427.3% in the 2nd quarter, Holdings Channel.com reports. The firm owned 109,680 shares of the biotechnology company’s stock after acquiring an additional 88,880 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in Vericel were worth $4,667,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. State of Wyoming increased its position in shares of Vericel by 3.8% in the 1st quarter. State of Wyoming now owns 10,428 shares of the biotechnology company’s stock worth $465,000 after purchasing an additional 381 shares during the last quarter. Maryland State Retirement & Pension System increased its position in shares of Vericel by 2.8% in the 2nd quarter. Maryland State Retirement & Pension System now owns 14,795 shares of the biotechnology company’s stock worth $630,000 after purchasing an additional 408 shares during the last quarter. Yousif Capital Management LLC increased its position in shares of Vericel by 2.9% in the 2nd quarter. Yousif Capital Management LLC now owns 19,044 shares of the biotechnology company’s stock worth $810,000 after purchasing an additional 532 shares during the last quarter. CW Advisors LLC increased its position in shares of Vericel by 0.3% in the 1st quarter. CW Advisors LLC now owns 182,866 shares of the biotechnology company’s stock worth $8,159,000 after purchasing an additional 593 shares during the last quarter. Finally, Truist Financial Corp increased its position in shares of Vericel by 1.0% in the 2nd quarter. Truist Financial Corp now owns 61,280 shares of the biotechnology company’s stock worth $2,607,000 after purchasing an additional 599 shares during the last quarter.

Vericel Stock Up 0.9%

Vericel stock opened at $36.32 on Friday. The firm has a 50-day moving average price of $33.68 and a two-hundred day moving average price of $38.10. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of 302.69 and a beta of 1.39. Vericel Corporation has a 52-week low of $29.24 and a 52-week high of $63.00.

Vericel (NASDAQ:VCEL) last posted its earnings results on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.03. The firm had revenue of $63.24 million during the quarter, compared to analyst estimates of $64.61 million. Vericel had a net margin of 2.85% and a return on equity of 2.47%. Vericel’s revenue was up 20.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.10) EPS. Research analysts expect that Vericel Corporation will post 0.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Zacks Research raised shares of Vericel from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. Canaccord Genuity Group decreased their price target on shares of Vericel from $61.00 to $58.00 and set a “buy” rating for the company in a report on Friday, August 1st. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Vericel in a report on Friday. BTIG Research lowered shares of Vericel from a “buy” rating to a “neutral” rating in a report on Wednesday, September 17th. Finally, Truist Financial decreased their price target on shares of Vericel from $46.00 to $41.00 and set a “buy” rating for the company in a report on Wednesday, October 15th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $58.40.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.